ArticleESMO real world data and digital oncology2026
HeCOG Cancer Biobank and Registry: a nationwide real-world resource for translational oncology research.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-standing cooperative oncology groups are uniquely positioned to generate high-quality real-world data in diverse tumor types. The Hellenic Cooperative Oncology Group (HeCOG), a nonprofit scientific organization, has established a multi-institutional clinical database and biobank to support translational cancer research and precision oncology initiatives. Our aim was to describe the structure, governance and operation of HeCOG Biobank and patient registry. Materials and methods: The HeCOG clinical database is a centralized, web-based platform that supports interventional, observational, real-world and translational studies across affiliated institutions. Clinical data are linked to biospecimens stored in the HeCOG Biobank, preserved at the Laboratory of Molecular Oncology. Biospecimen collection, processing, storage, and data handling are governed by standardized operating procedures. Results: To date, the registry includes >54 000 patients with diverse tumors, enrolled retrospectively and prospectively. The associated biobank comprises >17 000 formalin-fixed paraffin-embedded tumor tissue samples and >6000 blood-derived specimens. The largest tissue collections are from breast, colorectal, and lung cancer. Molecular and histopathological biomarker data are also available for several thousand patients within the registry. Biospecimens are uniquely coded and linked to pseudonymized longitudinal clinical, histopathological, and molecular data. Ongoing expansion includes digital pathology and radiological imaging datasets, further enhancing the translational potential of the resource. Conclusions: The HeCOG Biobank and the accompanying clinical database have evolved into a valuable resource for translational cancer research in Greece. Through the ongoing integration of digital pathology, imaging data, and artificial intelligence-based approaches it provides a strong basis for precision oncology and collaborative national and international research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.